Schering-Plough Will Eye Primary Care Acquisitions To Complement Vytorin, Zetia
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO Hassan vows not to repeat mistakes of Schering's past by relying on the cholesterol agents to carry the business for the long-term. Bayer's oral Factor Xa inhibitor is a potential acquisition candidate, depending on how the antithrombotic fares in Phase III.
You may also be interested in...
Schering-Plough Sets Acquisition Sights On Specialty Products
The company has entered the third – or “turnaround” – phase of its five-point restructuring program.
Schering-Plough Sets Acquisition Sights On Specialty Products
The company has entered the third – or “turnaround” – phase of its five-point restructuring program.
Schering-Plough Adds Levitra To Product Portfolio Through Deal With Bayer
Bayer abandons primary care market in U.S. and will cut 1,800 sales positions. Schering-Plough will take over marketing of Avelox and Cipro as well as Bayer's portion of Levitra co-promotion efforts.